Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Begoña Oliver

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
International Journal of Molecular Sciences|December 10, 2021
Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor EncephalitisNicolás Lundahl Ciano-Petersen, Pablo Cabezudo-García, Sergio Muñiz-Castrillo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2015
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseCarlos López-Gómez, Begoña Oliver-Martos, María-Jesús Pinto-Medel, et al.
Scientific Reports|August 20, 2017
Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatmentMaría Jesús Pinto-Medel, Begoña Oliver-Martos, Patricia Urbaneja-Romero, et al.
CNS Drugs|March 7, 2014
Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical responseJuan A García-León, Carlos López-Gómez, Teresa Orpez-Zafra, et al.
Neurobiology of Disease|February 25, 2019
The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosisCarolina Melero-Jerez, Margarita Suardíaz, Rafael Lebrón-Galán, et al.
Plos One|January 20, 2017
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNßIsaac Hurtado-Guerrero, Maria Jesús Pinto-Medel, Patricia Urbaneja, et al.
Scientific Reports|November 30, 2017
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathwayIsaac Hurtado-Guerrero, Maria Jesus Pinto-Medel, Patricia Urbaneja, et al.
Journal of Neurology|July 9, 2009
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)Oscar Fernández, Alfredo R-Antigüedad, María Jesús Pinto-Medel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 20, 2010
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational studyOscar Fernández, Marcos Papais Alvarenga, Miguel Guerrero, et al.
Bioanalysis|November 17, 2015
Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosisTeresa Órpez-Zafra, Jose Pavía, Maria J Pinto-Medel, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Sciences|December 10, 2021
Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor EncephalitisNicolás Lundahl Ciano-Petersen, Pablo Cabezudo-García, Sergio Muñiz-Castrillo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2015
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseCarlos López-Gómez, Begoña Oliver-Martos, María-Jesús Pinto-Medel, et al.
Scientific Reports|August 20, 2017
Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatmentMaría Jesús Pinto-Medel, Begoña Oliver-Martos, Patricia Urbaneja-Romero, et al.
CNS Drugs|March 7, 2014
Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical responseJuan A García-León, Carlos López-Gómez, Teresa Orpez-Zafra, et al.
Neurobiology of Disease|February 25, 2019
The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosisCarolina Melero-Jerez, Margarita Suardíaz, Rafael Lebrón-Galán, et al.
Plos One|January 20, 2017
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNßIsaac Hurtado-Guerrero, Maria Jesús Pinto-Medel, Patricia Urbaneja, et al.
Scientific Reports|November 30, 2017
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathwayIsaac Hurtado-Guerrero, Maria Jesus Pinto-Medel, Patricia Urbaneja, et al.
Journal of Neurology|July 9, 2009
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)Oscar Fernández, Alfredo R-Antigüedad, María Jesús Pinto-Medel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 20, 2010
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational studyOscar Fernández, Marcos Papais Alvarenga, Miguel Guerrero, et al.
Bioanalysis|November 17, 2015
Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosisTeresa Órpez-Zafra, Jose Pavía, Maria J Pinto-Medel, et al.
Pageof 5